Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 12/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.45 |
| ▸ | FEN1 | P39748 | 2/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406994 | 1.00 | GRM4 (0.54) | GRM4LRRK2ALOX5APFEN1FFAR2 | |
| SCHEMBL2404642 | 1.00 | GRM4 (0.54) | GRM4LRRK2ALOX5APFEN1FFAR2 | |
| SCHEMBL2408814 | 0.91 | GRM4 (0.47) | GRM4LRRK2ALOX5APFEN1 | |
| SCHEMBL19172439 | 0.91 | GRM4 (0.47) | GRM4LRRK2ALOX5APFEN1 | |
| SCHEMBL2408815 | 0.91 | GRM4 (0.47) | GRM4LRRK2ALOX5APFEN1 | |
| SCHEMBL29445482 | 0.91 | GRM4 (0.53) | GRM4LRRK2ALOX5APFEN1 | |
| SCHEMBL1936639 | 0.91 | GRM4 (0.53) | GRM4LRRK2ALOX5APFEN1 | |
| Trifluoroacetic Acid SCHEMBL2407542 | 0.88 | GRM4 (0.56) | GRM4LRRK2FFAR2FFAR4 | |
| SCHEMBL20689295 | 0.87 | GRM4 (0.42) | GRM4LRRK2ALOX5APFEN1FFAR4 | |
| SCHEMBL20687907 | 0.82 | ALOX5AP (0.43) | GRM4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539346-B1 | 4-[HETEROCYCLOALKYLOXY(HETERO)ARYLAMINO] THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2539346-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104337-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011104337-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, TNK2, CMPK1 | GRM4 3896/4885LRRK2 985/4885ALOX5AP 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.